-
2024-513724-42-00
10
Medulloblastoma
-
2024-514682-19-00
5
Resected pancreatic ductal adenocarcinoma
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517937-41-00
4
extensive stage small cell lung cancer (SCLC)
-
2024-519658-35-00
9
Primary localised prostate cancer
-
2025-521632-12-00
5
Patients on Factor Xa inhibitor treatment needing an urgent interventi
-
2025-522145-21-00
5
Metastatic hormone sensitive prostate cancer
-
2025-522580-15-00
4
Amyotrophic Lateral Sclerosis (ALS)
-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2025-523672-23-00
4
Metastatic Castrate Sensitive Prostate Cancer - mCSPC
-
2025-524408-30-01
5
Metastatic hormone-sensitive prostate cancer
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-512486-14-00
5
2026-01-22
Short Bowel Syndrome
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-520794-39-00
5
2025-12-10
Arterial Hypertension
-
2024-512922-27-00
4
2025-11-25
Mantle Cell Lymphoma (MCL)
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2024-518359-47-00
10
2025-06-17
Acute Myeloid Leukemia
-
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
-
2024-514517-35-00
5
2025-02-27
Acute myeloid leukemia
-
2023-504026-19-01
5
2024-06-05
Prostate Cancer
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i